SYL1001
Phase 3Small molecule
SYL1001 is one of 37 small molecule programs targeting Ocular pain. It is currently in Phase 3.
2
Indications
4
Total Trials
0
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
200 competitors in Eye Disease
#DrugCompanyPhaseTrials
1Chantix
PfizerPhase 3
Alphagan
AbbViePhase 3
Bayer Aspirin
BayerPhase 3
Zovirax
BBp Consulting, Inc
Phase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
CF101
CCan-Fite BioPharma
Phase 3
Carboxymethylcellulose
AbbViePhase 3
Refresh Plus
AbbViePhase 3
Cenegermin
DDompé Farmaceutici S.p.A
Phase 3
Diquafosol Tetrasodium
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Ocular pain2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SYL1001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSylentis, S.A.